



Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34th International Symposium on ALS/MND

November 28, 2023

Presentation to highlight preclinical data from ATH-1105, Athira's potential treatment candidate for amyotrophic lateral sclerosis (ALS)

BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- [Athira Pharma, Inc.](#) (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis (ALS) will be delivered at the upcoming [Motor Neurone Disease Association \(MNDA\) 34th International Symposium on ALS/MND](#), to be held December 6 – 8, 2023 in Basel, Switzerland.

Presentation Details:

Title: ATH-1105, a small molecule positive modulator of the neurotrophic hepatocyte growth factor system, is neuroprotective when administered prophylactically, therapeutically or in combination with riluzole in the prp-TDP-43 A315T mouse model of ALS

Session: 6A: Preclinical Therapeutic Strategies

Symposium Number: C57

Date/Time: Thursday, December 7, 12:15 – 12:30 p.m. CET

Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma

"We look forward to the presentation of these data, which highlight the potential of ATH-1105 as a treatment for ALS and add to the growing body of scientific and clinical data that support the potential benefits of our small molecule therapeutic candidates targeting the neurotrophic HGF system as novel treatments for neurodegenerative diseases," stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira. "These data, which include preclinical data showing prolonged survival and demonstrating consistent improvements in motor function, nerve function, biomarkers and nerve morphology in a transgenic mouse model of ALS, strongly support confidence in our plans to advance this program into human clinical studies in the first half of 2024."

The presentation is available on the [Scientific Publications & Presentations](#) page of the company's website at www.athira.com.

About ATH-1105

ATH-1105 is an orally administered small molecule designed to positively modulate the neurotrophic hepatocyte growth factor (HGF) system, which plays a critical role in nervous system maintenance and repair, including stimulation of cell survival, increase in neuronal outgrowth and modulation of neuronal network repair. In preclinical models of amyotrophic lateral sclerosis (ALS), ATH-1105 has been shown to significantly increase survival and delay time to death, enhance motor and nerve function, reduce motor neuron demyelination and axon degeneration, and improve biomarkers of neurodegeneration and inflammation.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates targeting the neurotrophic HGF system for Alzheimer's and Parkinson's disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit www.athira.com. You can also follow Athira on [Facebook](#), [LinkedIn](#), [X](#) (formerly known as Twitter) and [Instagram](#).

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer's disease, Parkinson's disease, Dementia with Lewy bodies, and other neurodegenerative diseases, such as amyotrophic lateral sclerosis; expectations regarding the potential efficacy and commercial potential of Athira's product candidates; and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "on track," "would," "expect," "plan," "believe," "intend," "pursue," "continue," "suggest," "potential," and other similar expressions, among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira's product candidates; development of product candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's product candidates with other treatments; Athira's assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira's clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira

undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Investor & Media Contact

Julie Rathbun

Athira Pharma

Julie.rathbun@athira.com

206-769-9219